Hepatitis E virus (HEV): The novel agent responsible for enterically transmitted non-A, non-B hepatitis

1991 ◽  
Vol 26 (S3) ◽  
pp. 142-147 ◽  
Author(s):  
Gregory R. Reyes ◽  
Patrice O. Yarbough ◽  
Albert W. Tam ◽  
Michael A. Purdy ◽  
Chiao-Chain Huang ◽  
...  
Keyword(s):  
Hepatitis E Virus ◽  
Hepatitis E ◽  
The Novel ◽  
Novel Agent

scholarly journals An Optimized High-Throughput Neutralization Assay for Hepatitis E Virus (HEV) Involving Detection of Secreted Porf2

Viruses ◽  
2019 ◽  
Vol 11 (1) ◽  
pp. 64 ◽  
Author(s):  
Chang Liu ◽  
Wei Cai ◽  
Xin Yin ◽  
Zimin Tang ◽  
Guiping Wen ◽  
...  
Keyword(s):  
High Throughput ◽  
Hepatitis E Virus ◽  
Hepatitis E ◽  
Neutralization Assay ◽  
The Novel ◽  
Specific Antibodies ◽  
Neutralizing Activity ◽  
Elisa Kit ◽  
Neutralizing Capacity ◽  
Potential Threshold

Hepatitis E virus (HEV) is a common cause of acute hepatitis worldwide. Current methods for evaluating the neutralizing activity of HEV-specific antibodies include immunofluorescence focus assays (IFAs) and real-time PCR, which are insensitive and operationally complicated. Here, we developed a high-throughput neutralization assay by measuring secreted pORF2 levels using an HEV antigen enzyme-linked immunosorbent assay (ELISA) kit based on the highly replicating HEV genotype (gt) 3 strain Kernow. We evaluated the neutralizing activity of HEV-specific antibodies and the sera of vaccinated individuals (n = 15) by traditional IFA and the novel assay simultaneously. A linear regression analysis shows that there is a high degree of correlation between the two assays. Furthermore, the anti-HEV IgG levels exhibited moderate correlation with the neutralizing titers of the sera of vaccinated individuals, indicating that immunization with gt 1 can protect against gt 3 Kernow infection. We then determined specificity of the novel assay and the potential threshold of neutralizing capacity using anti-HEV IgG positive sera (n = 27) and anti-HEV IgG negative sera (n = 23). The neutralizing capacity of anti-HEV IgG positive sera was significantly stronger than that of anti-HEV IgG negative. In addition, ROC curve analysis shows that the potential threshold of neutralizing capacity of sera was 8.07, and the sensitivity and specificity of the novel assay was 88.6% and 100%, respectively. Our results suggest that the neutralization assay using the antigen ELISA kit could be a useful tool for HEV clinical research.

scholarly journals Identification of a novel variant of hepatitis E virus in Austria: sequence, phylogenetic and serological analysis

2000 ◽  
Vol 81 (12) ◽  
pp. 2885-2890 ◽  
Author(s):  
Harald C. Worm ◽  
George G. Schlauder ◽  
Herbert Wurzer ◽  
Isa K. Mushahwar
Keyword(s):  
Recombinant Proteins ◽  
Hepatitis E Virus ◽  
Clinical Presentation ◽  
Acute Viral Hepatitis ◽  
Late Phase ◽  
Hepatitis E ◽  
The Novel ◽  
Serum Samples ◽  
Novel Variant ◽  
Acute Phase Serum

We isolated a novel hepatitis E virus (HEV-Au1) variant from a patient in Austria suffering from acute viral hepatitis, who had no known risk factors for acquiring hepatitis E. The clinical presentation and initial serological findings have been reported previously. In this paper we report the results of sequence and phylogenetic analysis of HEV products from viral RNA isolated from acute phase serum. The results show that HEV-Au1 is significantly divergent from other HEV isolates. The nucleotide identity of analysed fragments from the novel isolate ranges from 76·6 to 78·4% when compared to isolates from endemic regions and 84·6 to 87·9% when compared to isolates from non-endemic regions. Divergent results were obtained when serum samples taken from the convalescent phase of disease were tested with three different immunoassays (EIAs). An EIA based on United States isolate-specific peptides showed enhanced reactivity whereas EIAs based on recombinant proteins derived from prototype HEV strains from Burma and Mexico were unable to detect antibodies to HEV (anti-HEV) in late phase serum. The findings verify the presence of an additional HEV variant in an industrialized country and provide information about possible problems in detecting anti-HEV.

scholarly journals Identification of Hepatitis E Virus in the Feces of Red Foxes (Vulpes vulpes)

Animals ◽  
2020 ◽  
Vol 10 (10) ◽  
pp. 1841
Author(s):  
Zsófia Lanszki ◽  
Kornélia Kurucz ◽  
Safia Zeghbib ◽  
Gábor Kemenesi ◽  
József Lanszki ◽  
...  
Keyword(s):  
Hepatitis E Virus ◽  
Animal Species ◽  
Red Fox ◽  
Common Vole ◽  
Hepatitis E ◽  
The Novel ◽  
Red Foxes ◽  
Reverse Transcription Pcr ◽  
Wide Range ◽  
Dietary Origin

Orthohepeviruses (HEV) can infect a wide range of animals, showing a relatively strict host specificity; however, its zoonotic potential, natural transmission in the wildlife are less known. Several new HEV-like viruses have been identified in various animal species, including carnivores; however, the phylogenetic relationship among these viruses is poorly resolved, since some of them were known as rodent-related so far. The red fox, the most widespread carnivore worldwide, is a known reservoir of several viruses that transmit from wildlife to humans or domestic animals; they might have a defined role in the circulation of rodent-borne HEV. In this study, we performed a HEV survey by heminested RT-PCR (Reverse Transcription PCR) on red fox fecal samples to investigate the presence of HEV in red foxes living in natural conditions, and to explore the origin of the virus via phylogenetic analysis. Out of the 26 investigated samples, HEV RNA was identified in one sample. Following Sanger sequencing, the novel sequence displayed 91% identity on the nucleotide level with recently published European common vole-HEV derived from Microtus arvalis. In contrast, it shared 85% nucleotide similarity with HEV strains described previously in red foxes. Our results strongly support “the dietary-origin” of unclassified HEV-like strains described from predators that usually prey on rodents.

scholarly journals Isolation of Subtype 3c, 3e and 3f-Like Hepatitis E Virus Strains Stably Replicating to High Viral Loads in an Optimized Cell Culture System

Viruses ◽  
2019 ◽  
Vol 11 (6) ◽  
pp. 483 ◽  
Author(s):  
Mathias Schemmerer ◽  
Reimar Johne ◽  
Monika Erl ◽  
Wolfgang Jilg ◽  
Jürgen J. Wenzel
Keyword(s):  
Cell Culture ◽  
Culture System ◽  
Hepatitis E Virus ◽  
Calf Serum ◽  
Hepatitis E ◽  
Post Inoculation ◽  
The Novel ◽  
Cell Culture System ◽  
Wild Type ◽  
Viral Loads

The hepatitis E virus (HEV) is transmitted via the faecal–oral route in developing countries (genotypes 1 and 2) or through contaminated food and blood products worldwide (genotypes 3 and 4). In Europe, HEV subtypes 3c, 3e and 3f are predominant. HEV is the leading cause of acute hepatitis globally and immunocompromised patients are particularly at risk. Because of a lack of cell culture systems efficiently propagating wild-type viruses, research on HEV is mostly based on cell culture-adapted isolates carrying uncommon insertions in the hypervariable region (HVR). While optimizing the cell culture system using the cell culture-adapted HEV strain 47832c, we isolated three wild-type strains derived from clinical specimens representing the predominant spectrum of HEV in Europe. The novel isolates 14-16753 (3c), 14-22707 (3e) and 15-22016 (3f-like) replicate to high viral loads of 108, 109 and 106.5 HEV RNA copies/mL at 14 days post-inoculation, respectively. In addition, they could be kept as persistently infected cell cultures with constant high viral loads (~109 copies/mL) for more than a year. In contrast to the latest isolates 47832c, LBPR-0379 and Kernow-C1, the new isolates do not carry genome insertions in the HVR. Optimization of HEV cell culture identified amphotericin B, distinct salts and fetal calf serum (FCS) as important medium supplements. Overconfluent cell layers increased infectivity and virus production. PLC/PRF/5, HuH-7-Lunet BLR, A549 and HepG2/C3A supported replication with different efficiencies. The novel strains and optimized cell culture system may be useful for studies on the HEV life cycle, inactivation, specific drug and vaccine development.

Hepatitis E Virus in LeberBiopsien von Patienten mit akuter Hepatitis unbekannter Ätiologie

2011 ◽  
Vol 49 (01) ◽  
Author(s):  
C Dorloff ◽  
J Hemberger ◽  
M Odenthal ◽  
H Holzmann ◽  
S Aberle ◽  
...  
Keyword(s):  
Hepatitis E Virus ◽  
Hepatitis E

Severe course of Hepatitis E Virus infection in a patient with pre-existing autoimmune liver disease

2013 ◽  
Vol 51 (01) ◽  
Author(s):  
S Schlosser ◽  
J Pflaum ◽  
K Weigand ◽  
JJ Wenzel ◽  
W Jilg ◽  
...  
Keyword(s):  
Liver Disease ◽  
Virus Infection ◽  
Hepatitis E Virus ◽  
Hepatitis E ◽  
Autoimmune Liver Disease

Transfusion-transmitted hepatitis E virus infections: a risk for immunosuppressed patients

2018 ◽  
Vol 56 (01) ◽  
pp. E2-E89
Author(s):  
D Westhölter ◽  
J Hartl ◽  
J Hiller ◽  
U Denzer ◽  
S Peine ◽  
...  
Keyword(s):  
Hepatitis E Virus ◽  
Hepatitis E ◽  
Virus Infections ◽  
Immunosuppressed Patients

Hepatitis E Virus: No Evidence of Parenteral Transmission in Finland

1995 ◽  
Vol 74 (05) ◽  
pp. 1385-1386 ◽  
Author(s):  
Pirkko Pohjanpelto ◽  
Freja Ebeling ◽  
Vesa Rasi ◽  
Hartmut Hampl
Keyword(s):  
Hepatitis E Virus ◽  
Hepatitis E ◽  
Parenteral Transmission
Sign in / Sign up

Export Citation Format

Share Document